Guardant Health Inc.
Guardant Health Announces Open Market Sale Agreement Up to $400 Million
Summary
On August 23, 2024, Guardant Health, Inc. entered into an Open Market Sale Agreement with Jefferies LLC for an at-the-market offering program. The program allows the Company to offer and sell, at its discretion, shares of its common stock through Jefferies LLC, with aggregate gross proceeds of up to $400 million. The offering will be made pursuant to the Company's shelf registration statement on Form S-3, filed with the SEC on May 22, 2023. Jefferies LLC will receive compensation of up to 3.0% of the gross sales price per share. The Company has the right to terminate the Sales Agreement at any time.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement